Qiagen Expands Dx Footprint by Acquiring Stake in Alacris, EyeSense

Alacris Theranostics is using whole-genome sequence analysis to develop individualized cancer therapies while EyeSense is developing ophthalmic diagnostic systems for glucose monitoring of diabetes patients.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.